PEPTIDE CORTEXThe library
← The library

CJC-1295 (no DAC)

CJC-1295 (no DAC / Mod GRF 1-29)GH Axis
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis
MechanismGHRH analog without the Drug Affinity Complex (Modified GRF 1-29): a short-acting peptide, half-life around 30 minutes, distinct from CJC-1295 with DAC
EffectsSignals the GH axis; can affect body composition, fluid retention, and glucose
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published1 sourced
Community protocol — not clinically establishedCommunity guide — no DAC (Mod GRF 1-29)
RouteSubcutaneous
FrequencyOnce daily (pre-bed) most common; 1-2x daily in the "advanced" phase
Starting100 mcg once daily, weeks 1-2
Escalation150 mcg once daily weeks 3-4 ("Increase by 50 mcg only if initiation is tolerated")
Target200 mcg once daily, weeks 5-8 ("common maintenance level"); advanced 200-300 mcg 1-2x daily
CycleStandard 8-12 weeks on / 4-6 weeks off; short 4-6 weeks on / 2-4 weeks off

Fasted: at least 2 hours after eating and 30 minutes before eating again. No published human trial of the no-DAC variant at protocol scale.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; endocrine risks; avoid self-administration

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.